Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Muralikrishna Bhat

Internal Medicine Tucson, AZ Medical Doctor

NPI 1114914637 CMS profile 141485

1619 N Swan Rd, Tucson, AZ 85712

Open in the dashboard

General payments

$5,538

227 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Muralikrishna Bhat of Tucson, AZ is reported in the CMS Open Payments database as having received $5,538 across 227 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $819 33
2024 General $1,084 40
2023 General $958 26
2022 General $618 23
2021 General $583 35
2020 General $628 36
2019 General $848 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Muralikrishna Bhat
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Muralikrishna Bhat were reported at $819. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Muralikrishna Bhat Internal Medicine median Middle half National median
2019 $848 $159 $48–$570 $163
2020 $628 $119 $33–$402 $114
2021 $583 $135 $37–$521 $132
2022 $618 $141 $42–$496 $149
2023 $958 $149 $45–$519 $160
2024 $1,084 $154 $47–$537 $164
2025 $819 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,100 53 payments
  2. Novo Nordisk Inc $511 25 payments
  3. Pfizer Inc. $477 33 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $460 14 payments
  5. Amgen Inc. $361 14 payments
  6. Lilly USA, LLC $329 17 payments
  7. GlaxoSmithKline, LLC. $323 14 payments
  8. Mylan Specialty L.P. $183 3 payments
  9. Abbott Laboratories $160 3 payments
  10. Medtronic, Inc. $154 1 payment
  11. Other $1,480 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,538 227 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $404 19 payments
  2. Ozempic $378 20 payments
  3. RYBELSUS $276 16 payments
  4. ELIQUIS $247 17 payments
  5. SHINGRIX $173 11 payments
  6. MOUNJARO $170 8 payments
  7. YUPELRI $165 2 payments
  8. AIRSUPRA $161 10 payments
  9. FreeStyle Libre 3 $160 3 payments
  10. BREZTRI $156 10 payments
  11. Other $4,868 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 93 drugs

Part D claims

4,535

Median for Internal Medicine: 777

Drug cost

$507,314

Median for Internal Medicine: $73,373

Branded share of claims

18.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 72 $109,222
Jardiance Empagliflozin Brand 49 $67,648
Ozempic Semaglutide Brand 38 $60,611
Eliquis Apixaban Brand 53 $60,120
Farxiga Dapagliflozin Propanediol Brand 40 $58,314
Januvia Sitagliptin Phosphate Brand 23 $39,496
Xarelto Rivaroxaban Brand 14 $17,777
Spiriva Handihaler Tiotropium Bromide Brand 23 $16,047
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 17 $9,170
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $8,981

The 10 drugs with the highest cost, of 93 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$151,325

Of which drugs: $12,811

Medicare patients

337

Average age 76

Services billed

3,910

175 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 36%
Chronic kidney disease 28%
Diabetes 23%
Ischemic heart disease 23%
Depression 22%
Osteoporosis 20%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 23 23 $6,663
Vaccine for influenza for injection into muscle 90653 Office 58 58 $4,746

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $111
$111 — —
MOUNJARO
  • Lilly USA, LLC $61
$61 72 —
VRAYLAR
  • AbbVie, Inc. $61
$61 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $45
$45 — —
ZEPBOUND
  • Lilly USA, LLC $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record